From 8cf2177a0f60b7bf4bde3e44fa8d4bbd719d7c90 Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Mon, 19 Feb 2024 15:54:16 +0100 Subject: [PATCH] [logseq-plugin-git:commit] 2024-02-19T14:54:15.057Z --- pages/STOP2030___Web.md | 7 ++++--- 1 file changed, 4 insertions(+), 3 deletions(-) diff --git a/pages/STOP2030___Web.md b/pages/STOP2030___Web.md index af6f0597..4045407d 100644 --- a/pages/STOP2030___Web.md +++ b/pages/STOP2030___Web.md @@ -35,11 +35,11 @@ - - Ideas generales importantes - Dosing strategies for Ivermectine are being revisited - - The fix-dose coformulation of Albendazole/Ivermectine is [[due]] to enter regulatory agencies + - The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies - Acceptability and safety studies are underway - The access plan is being developed - Integration across programs (these results have implications beyond STH) - - [[Progress]] has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal. + - Progress has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal. - El abstract del proyecto? - [[Soil-Transmitted Helminths]] (STH) remain a significant public health problem with recognized obstacles for control and elimination with the current benzimidazole regimens in [[Mass Drug Administration]] (MDA) campaigns. Renewed targets from [[WHO]] for 2030 include elimination of [[STH]] morbidity in pre-school and school age children (PSAC & SAC), increased country governance and financial support and a strongyloidiasis control program; 2030 has also been targeted by [[WHO]] for controlling NTDs to attain the Sustainable Development Goals. @@ -48,5 +48,6 @@ This [[project]], [[STOP2030]], seeks to complement the results of the safety and efficacy trial with a field-based safety and effectiveness clinical study, acceptability studies in [[Ghana]] and [[Kenya]], modelling and cost-effectiveness exercises. The resulting information will be consolidated to build a multidisciplinary package for policy making and [[WHO]] guidance with the support of advocacy and communication activities to reach stakeholders and maximize the exploitation and impact of the [[FDC]] for [[STH]] control and elimination. The Consortium assembled to execute the [[STOP2030]] proposal combines expertise in complementary fields [[from]] program assessment and implementation through Ministries of [[Health]] in sub Saharan African countries, advocacy, state of the art technology, leadership in clinical research and a pharma that has shown commitment for generating access to drugs against NTDs and has recently obtained [[WHO]] prequalification for generic ivermectin #INFO - - [[Project duration (36 months); cuando empieza y cuando acaba (20 junio 2026) + - Project duration (36 months); cuando empieza y cuando acaba (20 junio 2026) + - - \ No newline at end of file